<DOC>
	<DOCNO>NCT01931163</DOCNO>
	<brief_summary>RATIONALE : Everolimus plus Cisplatin may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : The purpose study test effective combing Cisplatin chemotherapy Everolimus treat subject residual triple negative breast cancer , already receive chemotherapy prior surgery .</brief_summary>
	<brief_title>NECTAR Everolimus Plus Cisplatin Triple ( - ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Female patient ≥18 year age . 2 . Clinical/pathological documentation residual disease neoadjuvant therapy . 3 . Patients synchronous bilateral cancer eligible : • Index cancer triplenegative , define ER , PR , HER2 . 4 . HER2 negative tumor . HER2 negativity must confirm one following : FISHnegative ( FISH ratio &lt; 2.2 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.2 ) . 5 . Estrogen receptor negative progesterone receptor negative ( &lt; 10 % stain IHC estrogen receptor progesterone receptor ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 7 . Adequate hematologic function , define : Absolute neutrophil count 2 &gt; 1000/mm3 Platelet count ≥100,000/mm3 Hemoglobin &gt; 9 g/dL 8 . Adequate liver function , define : AST ALT ≤2.5 x upper limit normal ( ULN ) Total bilirubin ≤1.5 x ULN ( unless patient grade 1 bilirubin elevation due Gilbert 's disease similar syndrome involve slow conjugation bilirubin ) . 9 . Adequate renal function , define : • Serum creatinine ≤1.5 x ULN 10 . Complete stag workup ≤24 week prior initiation study treatment compute tomography ( CT ) scan chest abdomen/pelvis ( abdomen/pelvis prefer ; abdomen accept ) , CT scan head MRI brain ( symptomatic ) , either positron emission tomography ( PET ) scan bone scan . 11 . Adequate cardiac function , define leave ventricular ejection fraction ( LVEF ) value &gt; 50 % ( normal per institutional guideline ) MUGA scan echocardiogram ( ECHO ) . 12 . Patients previous history invasive cancer ( include breast cancer ) eligible definitive treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . 13 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 14 . Patient must accessible treatment followup . 15 . Women childbearing potential must agree use acceptable method birth control avoid pregnancy duration study treatment , 3 month thereafter . 16 . Able swallow retain oral medication . 17 . Patient must willing undergo breast biopsy require study protocol . 18 . All patient must able understand investigational nature study give write informed consent prior study entry . 1 . Women pregnant breastfeeding . 2 . History previously treat ductal carcinoma situ ( DCIS ) acceptable . 3 . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . 4 . Known intolerance hypersensitivity Everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) ; 5 . Previous cancer ( exception nonmelanoma skin cancer cervical carcinoma situ ) past 5 year . 6 . Patients severe and/or uncontrolled medical condition : 1. unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior start Everolimus , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease 2 . Symptomatic congestive heart failure New York heart Association Class III IV 3. active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , chronic hepatitis ( i.e . quantifiable HBVDNA and/or positive HbsAg , quantifiable HCVRNA ) , 4. know severely impaired lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) , 5. active , bleeding diathesis ; 7 . Patients may receive investigational anticancer treatment participate study . 8 . Concurrent severe , uncontrolled infection intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 9 . Mental condition would prevent patient comprehension nature , risk associate , study . 10 . Inability comply study and/or followup procedure . 11 . Patients receive live attenuate vaccine within 1 week start Everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine ; 12 . Known history HIV seropositivity ; 13 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , unless use highly effective method contraception dose study treatment . Highly effective contraception method include combination two follow ( a+b a+c b+c ) : 1 . Use oral , injected implant hormonal method contraception ; 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository ; 4 . Total abstinence ; 5 . Male/female sterilization . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider childbearing potential . 14 . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>